Cargando…
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
After the discovery of activating mutations in EGFR, EGFR tyrosine kinase inhibitors (TKIs) have been introduced into the first-line treatment of non-small-cell lung cancer (NSCLC). A series of studies have shown that EGFR TKI monotherapy as first-line treatment can benefit NSCLC patients harbouring...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650459/ https://www.ncbi.nlm.nih.gov/pubmed/29088904 http://dx.doi.org/10.18632/oncotarget.20095 |